Omni Bio Pharmaceutical Intends To Expand Type 1 Diabetes Trial To 50 Patients

Omni Bio Pharmaceutical, Inc. (“Omni Bio”), an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50…
Diabetes News From Medical News Today

Responses are currently closed, but you can trackback from your own site.

Comments are closed.

Copyright 2010 DiabetesSigns.org, Inc. All rights reserved. The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments. See the Terms of Service for more information. Privacy Policy

Powered by Yahoo! Answers